Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zynerba’s Cannabidiol Failure in Focal Seizures Not So Clear-Cut

Executive Summary

Zynerba’s gel formulation of cannabidiol has disappointed in top-line data from a Phase II study in epilepsy patients with focal seizures, but some signals of efficacy in a companion study, and expected data from studies in two other indications, might influence future development plans.

You may also be interested in...



Zynerba Sketches Phase III Plan For Cannabinoid Gel In Fragile X

Positive Phase II study of cannabinoid ZYN002 sends stock soaring, but the trial was very small with an open-label design, and response was mostly recorded by caregivers.

Critical Clinical Trial Updates Expected in 3Q

Ten clinical trial data readouts to watch for in the third quarter of 2017 that are expected to shift stocks and potentially change standard of care options in some disease areas.

Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well

Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC099284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel